@article{78a8d30123c543b88d4b953df0fe882a,
title = "Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms",
keywords = "adoptive T cell therapy, cancer, immune checkpoint blockers, immunotherapy, tumor microenvironment",
author = "Janin Chandra and Morten Hansen and Nathalie Labarriere and Ilaria Marigo and Fernando Souza-Fonseca-Guimaraes and Lazar Vujanovic and Yoshinobu Koguchi and Nicolas Jacquelot",
note = "Funding Information: YK receives funding from Tesaro, a GSK company, Bristol-Myers Squibb, and Shimadzu Corporation. LV is a co-inventor of a methodology licensed to INmune Bio, Inc. where a selective inhibitor of soluble TNF can be used to prevent or treat malignancies. MH receives funding from ImmuniTrack A/S as part of a consultancy agreement. Funding Information: This work was supported by grants from Cure Cancer Australia and Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme (APP1163990 to NJ, 1158085 to FS-F-G), Cancer Council NSW (RG21-05 to NJ), the US Department of Defense – Breast Cancer Research Program – Breakthrough Award Level 1 (#BC200025 to FSFG), a ANZSA Sarcoma Research Grant (supported by Kicking Goals for Xav, Stoney{\textquoteright}s Steps and Stop Sarcoma to FS-F-G), National Institute of Dental & Craniofacial Research (LV; 1R01DE031947-01), Euronanomed 2019-135 and 2021-014 (IM) and a UQ Diamantina Institute Laboratory Start-Up Package (to FS-F-G). ",
year = "2022",
month = jun,
day = "2",
doi = "10.3389/fimmu.2022.939789",
language = "English",
volume = "13",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
}